Protagonist Therapeutics Inc (PTGX)

Return on equity (ROE)

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Net income (ttm)	US$ in thousands	162,110	-78,955	-140,484	-137,611	-140,188	-127,393	-130,106	-132,678	-122,483	-125,551	-107,530	-81,489	-70,068	-66,150	-64,765	-73,411	-83,164	-77,187	-73,551	-65,877
Total stockholders’ equity	US$ in thousands	560,444	336,677	302,149	294,068	216,167	215,608	243,616	267,978	301,778	300,021	329,660	357,447	259,334	279,606	169,590	167,485	62,666	79,964	95,358	84,316
ROE		28.93%	-23.45%	-46.49%	-46.80%	-64.85%	-59.09%	-53.41%	-49.51%	-40.59%	-41.85%	-32.62%	-22.80%	-27.02%	-23.66%	-38.19%	-43.83%	-132.71%	-96.53%	-77.13%	-78.13%

March 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $162,110K ÷ $560,444K
= 28.93%

Protagonist Therapeutics Inc's Return on Equity (ROE) has shown significant fluctuations over the past 20 quarters. The most recent ROE of 28.93% as of March 31, 2024, indicates a strong return generated by the company for its shareholders. This is a positive sign as it shows the company's ability to generate profit from the shareholders' equity.

However, the company experienced negative ROE values in several quarters, with the lowest being -132.71% as of March 31, 2020. Negative ROE values can be a cause for concern as it indicates that the company is not effectively utilizing shareholder funds to generate profits.

The negative ROE values observed in the past could be attributed to various factors such as operational inefficiencies, high debt levels, or poor financial performance. It is important for Protagonist Therapeutics Inc to closely monitor its ROE and take necessary measures to improve profitability and efficiency in order to enhance shareholder value in the long run.